Biotech Collaboration Strategy With IGI's Cyril Konto, M.D.
Streams straight from the publisher. podnod never proxies or re-hosts episode audio.
We love to hear from our listeners. Send us a message.
On this week's episode, Cyril Konto, M.D., president, executive director, and CEO at Ichnos Glenmark Innovation (IGI) talks about the promise of multi-specific antibodies, funding the company during the 'biotech winter,' closing a $700 million upfront licensing deal with AbbVie, the impact of China's rising biotech sector, and the keys to successful collaboration. Cyril also discusses IGI's focus on developing innovative therapies for emerging markets, and the shift from animal models to in silico modeling in preclinical research.
Access this and hundreds of episodes of the Business of Biotech videocast under the Business of Biotech tab at lifescienceleader.com.
Subscribe to our monthly Business of Biotech newsletter.
Get in touch with guest and topic suggestions: ben.comer@lifescienceleader.com
Find Ben Comer on LinkedIn: https://www.linkedin.com/in/bencomer/
We love to hear from our listeners. Send us a message.
buzzsprout.comBusiness of Biotech
lifescienceleader.comBusiness of Biotech newsletter
www9.lifescienceleader.comhttps://www.linkedin.com/in/bencomer/
linkedin.com
- 0:00Meet IGI And Cyril Konto
- 2:00From Big Pharma To Biologics
- 5:20Surviving The Biotech Winter
- 10:30Shutting Manufacturing And Moving To CDMOs
- 14:20Why IGI’s Alliance Model Exists
- 18:00Building Culture Across Three Regions
- 21:20Collaboration As An Operating System
- 25:10Inside The $700M AbbVie Deal
- 31:00Keeping Emerging Market Rights
- 34:00Modality Strategy: Multi-Specifics And A Small Molecule
- 37:00The BEAT Platform Explained Simply
- 40:00Why Tri-Specifics And What Comes Next
- 44:00Personalization Without Narrowing Patients
- 47:00China’s Capital Shift And IGI’s Response
- 52:00Rethinking Preclinical: In Silico Over Animals
- 56:00Near-Term Milestones And IPO Readiness
- 58:10Closing And Where To Subscribe